(Q45224217)

English

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study

scientific article published on 14 January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

0 references

schizoaffective disorder

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shlomo Brook

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Jeorg Walden

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Isma Benattia

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Cynthia O Siu

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Steven J Romano

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

publication date

14 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

178

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

514-523

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

https://scigraph.springernature.com/pub.10.1007/s00213-004-2082-5

0 references

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Symptomatic volunteers in multicenter drug trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15650846

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-004-2082-5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45224217&oldid=2151471914"